Shares of Imprivata Inc. (NYSE:IMPR) have been given a consensus recommendation of “Hold” by the ten research firms that are covering the firm. Seven equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $16.00.

A number of equities research analysts have weighed in on IMPR shares. Stifel Nicolaus cut Imprivata from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. Zacks Investment Research upgraded Imprivata from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Wednesday, June 29th. Piper Jaffray Cos. cut Imprivata from an “overweight” rating to a “neutral” rating in a research note on Wednesday, July 13th. Leerink Swann cut Imprivata from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 14th. Finally, Wells Fargo & Co. cut Imprivata from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 2nd.

Imprivata (NYSE:IMPR) remained flat at $19.26 during trading on Thursday. Imprivata has a one year low of $9.00 and a one year high of $19.28. The stock has a 50-day moving average price of $19.24 and a 200-day moving average price of $15.96.

Imprivata (NYSE:IMPR) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.05. Imprivata had a negative return on equity of 49.06% and a negative net margin of 18.17%. Equities research analysts anticipate that Imprivata will post ($0.44) EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Gilder Gagnon Howe & Co. LLC acquired a new position in Imprivata during the second quarter valued at about $3,601,000. Emerald Mutual Fund Advisers Trust raised its stake in Imprivata by 4.5% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 624,927 shares of the company’s stock valued at $8,749,000 after buying an additional 27,000 shares during the period. Essex Investment Management Co. LLC purchased a new stake in Imprivata during the second quarter valued at $595,000. Strs Ohio raised its stake in Imprivata by 29.4% in the second quarter. Strs Ohio now owns 44,000 shares of the company’s stock valued at $616,000 after buying an additional 10,000 shares during the period. Finally, Profit Investment Management LLC purchased a new stake in Imprivata during the second quarter valued at $1,848,000. Hedge funds and other institutional investors own 59.34% of the company’s stock.

About Imprivata

Imprivata, Inc is engaged in providing healthcare information technology (IT) solutions. The Company’s IT security and identity platform provides authentication management, fast access to patient information, secure communications and positive patient identification products to the healthcare industry.

5 Day Chart for NYSE:IMPR

Receive News & Stock Ratings for Imprivata Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprivata Inc. and related stocks with our FREE daily email newsletter.